| Biomarker ID | 655 |
| PMID | 21592298 |
| Year | 2011 |
| Biomarker | enhancer of zeste homologue 2 (EZH2) |
| Biomarker Basis | Expression Based |
| Biomolecule | Protein |
| Source | Tissue |
| Subjects | Humans |
| Regulation | Progression Vs No Progression |
| Odds Ratio/Hazard Ratio/Relative Risk | Univariate: RR: 2.0, (95% CI: 1.2–3.3) |
| Effect on Pathways | Pathways Include:- Cell differentiation pathway,MicroRNAs in muscle cell differentiation, PRC2 complex long-term gene silencing through modification of histone tails,Interleukin-2 signaling pathway |
| Experiment | Progression Free Survival Vs No Progression Free Survival |
| Type of Biomarker | Prognostic |
| Cohort | 247 patients with prostate cancer were undertaken for the study. GS distribution was as follows: GS < 7, n = 60 (24.3%); GS = 7, n = 79 (32.0%); and GS > 7, n = 108 (43.7%). |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | p=0.004 |
| Method Used | Immunohistochemistry |
| Clinical | No |
| Remarks | Did not reach statistical significance in multivariate models |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | EZH2 |